XCUR News and Press, Exicure Inc. From 05/16/22

Exicure press release (NASDAQ:XCUR): Q1 GAAP EPS of -$0.07. Revenue of $2.57M (+157.0% Y/Y). Cash, cash equivalents and short-term investments were $27.6 million as of March 31, 2022, as compared to $48.3 million as of December 31, 2021 For further details see: Exicure GAAP EPS of -$0.0...

Recently announced a $5.0 million raise in a private placement transaction led by a subsidiary of CBI Co., Ltd. (“CBI”), a member of a leading investment group in South Korea focusing on assisting scientific-based companies in South Korea and the United States ...

Exicure (NASDAQ:XCUR) agreed to sell 26.02M shares at a purchase price of $0.1937/share to certain accredited investors in a private placement in public equity financing. The purchase price represents an ~45% premium to 10-day volume weighted-average share price from May 9, 2022. Gr...

Proceeds expected to support Exicure’s continued advancement of preclinical candidates including its SCN9A product candidate, a non-opioid pain analgesic The private placement is being led by a subsidiary of CBI Co., Ltd. (“CBI”), a member of a leading inv...

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a poster presentation at TIDES USA 2022, May 9-12, 2022. Poster presentation: “Development of Spherical Nucleic Ac...

3 Penny Stocks to Add to Your Watchlist This Week There are a number of ways to find penny stocks that may be worth investing in. Before going any further, it’s crucial to understand your own investing style and goals. Some people are willing to take on more risk for the potentia...

3 Penny Stocks to Add to Your Watchlist With New Fed Updates Right now, the major focus of the stock market and penny stocks is moves being made by the Federal Reserve. On April 6th, the Fed announced a plan to shrink the balance sheet by roughly $95 billion per month. It will do this b...

Exicure (NASDAQ:XCUR) stock sinks 21% postmarket after the firm posted weak 2021 results and raised concern over its ability to continue as a going concern in the next 1 year. Revenue was -$0.5M in 2021, down $17.1M from 2020, due to a decrease in non-cash revenue of $19.3M associated with XC...

Exicure press release (NASDAQ:XCUR): FY GAAP EPS of -$0.72. Revenue of -$0.5M (-103.0% Y/Y). The company said this decrease in revenue is mostly due to a decrease in non-cash revenue of $19.3M associated with the Company’s collaboration with AbbVie partially offset by the recognition o...

Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022 Continues progression of work with partnered programs, with plan of meeting potential pre-clinical milestones in 202...